Next Article in Journal
Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer
Next Article in Special Issue
The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer
Previous Article in Journal
Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine
Previous Article in Special Issue
Increased Soluble CMG2 Serum Protein Concentration Is Associated with the Progression of Prostate Carcinoma
Open AccessReview

Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer

Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1153; https://doi.org/10.3390/cancers11081153
Received: 24 July 2019 / Revised: 8 August 2019 / Accepted: 9 August 2019 / Published: 12 August 2019
(This article belongs to the Special Issue Prostate Cancer: Past, Present, and Future)
  |  
PDF [626 KB, uploaded 12 August 2019]
  |  

Abstract

Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance to systemic therapies. Inflammation, which is induced by various factors such as infection, microbiome, obesity, and a high-fat diet, is the major etiology in the development of prostate cancer. Inflammatory cells play important roles in tumor progression. Various immune cells including tumor-associated neutrophils, tumor-infiltrating macrophages, myeloid-derived suppressor cells, and mast cells promote prostate cancer via various intercellular signaling. Further basic studies examining the relationship between the inflammatory process and prostate cancer progression are warranted. Interventions by medications and diets to control systemic and/or local inflammation might be effective therapies for prostate cancer progression. Epidemiological investigations and basic research using human immune cells or mouse models have revealed that non-steroidal anti-inflammatory drugs, metformin, statins, soy isoflavones, and other diets are potential interventions for preventing progression of prostate cancer by suppressing inflammation. It is essential to evaluate appropriate indications and doses of each drug and diet. View Full-Text
Keywords: inflammation; prostate cancer; immune cell; intervention; NSAIDs; metformin; statin; cytokine; mouse model inflammation; prostate cancer; immune cell; intervention; NSAIDs; metformin; statin; cytokine; mouse model
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Hayashi, T.; Fujita, K.; Matsushita, M.; Nonomura, N. Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer. Cancers 2019, 11, 1153.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top